Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. (Q33372916)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. |
scientific article |
Statements
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study (English)
C Tournigand
L Mineur
R Fellague-Chebra
M Flesch
M Mabro
M Hebbar
S Postel Vinay
C Louvet
A de Gramont
GERCOR (French Oncology Research Group)
9 October 2006